DIRS.INFO The most relevant business & tech news

☆ Trump says he will give RFK Jr. a major health role if he wins the White House. Here's what that means for patients, drugmakers
▼ + stars: | 2024-11-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +10 min

Some health experts said elevating Kennedy, even in an informal Trump administration position, could potentially lead to severe consequences for patients, drugmakers and the nation's public health overall. That could exacerbate the nation's existing public health challenges, such as declining childhood vaccination rates for several preventable diseases, some experts say. "I think we could reasonably predict that there would be a decline in vaccination rates among children, and perhaps vaccination overall." Drugmakers such as Pfizer and Moderna are still recovering from falling Covid vaccination rates in the U.S., which have dented their profits over the last two years. Kennedy's other proposals for overhauling federal health agencies will likely be difficult to execute.

Persons: Donald Trump, Robert F, Kennedy Jr, Anna Moneymaker, Kennedy, Trump, Dr, Paul Offit, Drew Altman, Altman, Genevieve Kanter, Cynthia Blancas, Deep Patel, Christina House, they've, Offit, Andrew Kelly, USC's Kanter, that's, Georges Benjamin, Covid, Kanter Organizations: Gas, Getty, White House, Trump, Children's Hospital of Philadelphia, CNBC, and Drug Administration, Centers for Disease Control, Commonwealth Fund, Senate, Washington Post, University of Southern, CVS, Los Angeles Times, CDC, Pfizer, Moderna, NBC, Health Defense, FDA, Department of Health, Human Services, U.S . Food, Drug Administration, Reuters, American Public Health Association, Pharma Locations: Duluth , Georgia, U.S, University of Southern California, Lynwood, Huntington Park, Samoa, White Oak , Maryland

☆ Tariffs could have trickle-down effects across global pharmaceutical industry, says CEO
▼ + stars: | 2024-11-04 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTariffs could have trickle-down effects across global pharmaceutical industry, says CEOJohn Graham, Group CEO of Zuellig Pharma, talks about election risks, US-China tensions, and how tariffs and protectionism could affect the pharmaceutical industry.

Persons: John Graham Organizations: Zuellig Pharma Locations: China

In Wisconsin’s hotly contested U.S. Senate race, Republican Eric Hovde has focused much of his closing messaging on attacking the finance career of Democratic Sen. Tammy Baldwin’s girlfriend, highlighting their same-sex relationship. Another Hovde campaign ad features a narrator talking about Baldwin’s relationship with Brisbane. “This is Sen. Tammy Baldwin,” the narrator says. Now vying for a third Senate term, Baldwin has said the attacks are designed to distract from her record. Baldwin campaign officials and LGBTQ rights organizations said that Hovde’s attack lines amount to a cynical ploy by Republicans.

Persons: Republican Eric Hovde, Democratic Sen, Tammy Baldwin’s, Maria Brisbane, ”, ” Baldwin, Baldwin, ” “ Tammy, Sen, Tammy Baldwin, Tammy doesn’t, Morgan Stanley, MSNBC’s “ Andrea Mitchell, Eric Hovde, Hovde, “, “ Eric Hovde, —, Zach Bannon, “ Sen, Sarah Kate Ellis, ” Kelley Robinson, ” Robinson, GLAAD didn’t, Andrew Mamo, ” “, Donald Trump Organizations: U.S, Senate, Republican, Democratic, Wall Street, Maria’s, Republicans ’, Baldwin TV, U.S . Senate, Big Pharma, ”, CNN, Banking, Human Rights, GLAAD Locations: Brisbane, Wisconsin, New York City , Wisconsin, New York, California

☆ Novartis CEO on the impact of the U.S. election for pharma
▼ + stars: | 2024-10-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis CEO on the impact of the U.S. election for pharmaNovartis CEO Vas Narasimhan talks to CNBC about the company's latest results and the potential impact of the U.S. election on the business.

Persons: Vas Narasimhan Organizations: Novartis, pharma Novartis, CNBC

☆ How activist Starboard may help boost value in Kenvue's skin and beauty business
▼ + stars: | 2024-10-26 | by ( Kenneth Squire | ) www.cnbc.com time to read: +8 min

The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Self Care product categories include pain care; cough cold allergy; and "other self care." The Skin Health and Beauty segment's product categories include face and body care and hair, sun and others. Skin Health and Beauty has been proven to be a marketing business whose growth can be greatly aided by social media. Kenvue has a solid business with iconic brands and one underperforming segment in Skin Health and Beauty.

Persons: Russell, Johnson, Kenvue, Michael CeraVe, Ken Squire Organizations: Skin, Health, Self, pharma, Colgate, Palmolive, Haleon, Kenvue, Essential Health, L'Oreal, Beauty, Skin Health, Management, 13D Locations: North America, Asia, Europe, Middle East, Africa, America, CY19, CeraVe

☆ What activist hedge fund Starboard wants from Pfizer
▼ + stars: | 2024-10-22 | by ( Alex Nicoll | Kaja Whitehouse | ) www.businessinsider.com time to read: +3 min

Activist hedge fund Starboard has taken a stake in drug giant Pfizer. AdvertisementActivist hedge fund manager Jeff Smith outlined his concerns about drugmaker Pfizer on Tuesday but stopped short of offering a solution — saying that's a job for the board of directors. He also shared a version of the presentation his hedge fund Starboard presented to Pfizer officials at a meeting last week. "We all get measured by our track record," Smith told the crowd. The track record is not great during this period of time in the pharma industry."

Persons: execs, —, Jeff Smith, Smith, Pfizer, It's, I'm Organizations: Pfizer, Service, 13D, pharma Locations: Manhattan, Central, Olive Garden

☆ CNBC Pro Talks: China portfolio manager reveals what he's buying right now
▼ + stars: | 2024-10-22 | by ( Cnbc.Com Staff | ) www.cnbc.com time to read: +2 min

As investors ponder how — and where — to invest in China, CNBC's Tanvir Gill will quiz China portfolio manager Jason Hsu on where he sees opportunities in the current market. Hsu previously told CNBC Pro that he was betting on tech — and artificial intelligence in particular — for the long term. Hsu set up Ranmore Fund Management in 2016, prior to which he was co-founder and vice chairman of quantitative asset manager Research Affiliates. Join CNBC Pro Talks on Wednesday, Oct. 23 at 6:30 a.m. BST / 1:30 p.m. SGT / 1:30 a.m. Learn more from our previous Pro Talks: How to play AI in a cheaper way without owning stocks like Nvidia, according to fund manager Fund manager reveals his worst trade of the year — and the lessons he learned Beyond Novo: Fund manager likes this under-the-radar pharma stock Related coverage from Pro: Is it time to invest in China?

Persons: Finance Lan Fo'an, CNBC's Tanvir Gill, Jason Hsu, Hsu, Goldman, Tanvir Gill Organizations: Finance, China's CSI, Rayliant Global Advisors, China Equity, CNBC Pro, China Equity ETF, Ping An Insurance, Midea, Ranmore Fund Management, Research, Anderson School of Management, UCLA, Nvidia, pharma, Wall, Citi Locations: China

☆ TikTok once planned to use content posted by its users to influence Mitch McConnell, lawsuit reveals
▼ + stars: | 2024-10-20 | by ( Kenneth Niemeyer | ) www.businessinsider.com time to read: +3 min

Attorneys general from 14 states are suing TikTok over claims it harms children's mental health. One document shows how the company planned to influence Sen. Mitch McConnell. Now, internal TikTok documents included in the state lawsuits are shedding new light on how TikTok tried to influence Congress during its debate on a potential ban. One of those documents revealed that TikTok planned to use content from its users to sway lawmakers, including influential Sen. Mitch McConnell, who supported the TikTok ban. Advertisement"As is standard practice at other companies, we also monitor public sentiment on issues that relate to the company," TikTok said.

Persons: TikTok, Sen, Mitch McConnell, —, McConnell Organizations: TikTok, Service, Purdue Pharma, Congress, United States, Lawmakers, Kentucky Public Radio, NPR, Kentucky Public Locations: United, Kentucky

☆ In the competitive world of pharma, companies need to focus on worker well-being to retain top talent, says Ferring's HR exec
▼ + stars: | 2024-10-15 | by ( Julia Hood | ) www.businessinsider.com time to read: +7 min

She said that Ferring has grown more intentional about focusing on worker well-being, which is particularly important for the highly competitive field of healthcare. What are the benefits for companies focused on worker well-being? We've defined well-being in a holistic way, so it's not just about physical well-being; it's also about mental well-being and financial well-being. What advice do you have for other companies that are just getting started thinking about DEI and worker well-being initiatives? What policies demonstrate your focus on worker well-being?

Persons: —, Johnson, JP Morgan, Ferring, We've, it's, I've, we've, you've Organizations: Ferring Pharmaceuticals, Service, gastroenterology, Johnson, American Express, Pharma, pharma Locations: Swiss, Switzerland

☆ Jefferies says buy this little-known injectable drug delivery maker with more than 30% upside
▼ + stars: | 2024-10-14 | by ( Samantha Subin | ) www.cnbc.com time to read: +1 min

It's time to buy shares of this under-the-radar injectable delivery and beauty packaging maker with more than 30% upside potential, according to Jefferies. Analyst Daniel Rizzo upgraded shares of Aptargroup to a buy rating, saying that new pharmaceutical delivery products should drive 10% sales growth on a compound annual basis through 2027. Along with the upgrade, Rizzo boosted his price target by 39% to $215 a share, representing 33% upside from Friday's close. The firm also forecasts that the company can drive 7% to 11% pharmaceuticals sales growth over the next 10 years, given that 80% of its delivery systems are protected by intellectual property tools such as patents. "The stock is up ~30% YTD ... but as new products help earnings accelerate, we expect multiple expansion to help support another ~30% increase."

Persons: Daniel Rizzo, Rizzo Organizations: Jefferies, OTC Narcan, pharma Locations: Aptargroup, U.S

☆ Here are Monday's biggest analyst calls: Nvidia, Broadcom, Apple, Tesla, Flutter, Caterpillar, Alphabet & more
▼ + stars: | 2024-10-14 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are the biggest calls on Wall Street on Monday: TD Cowen reiterates Nvidia as buy TD said Nvidia remains a top pick at the firm. Goldman Sachs upgrades Ibotta to buy from neutral Goldman Sachs reiterates Alphabet as buy Goldman lowered its price target on the stock to $208 per share from $217 citing a slew of headwinds for Alphabet. Wells Fargo upgrades Flutter to overweight from equal weight Wells says investors should buy the dip in shares of the gambling company. Goldman Sachs downgrades AutoZone to sell from buy Goldman downgraded the auto parts retailer due to "muted growth." Goldman Sachs upgrades Ibotta to buy from neutral Goldman says it likes the growth opportunity for the mobile tech company.

Persons: TD Cowen, Mizuho, Goldman Sachs, Goldman, Wells, Truist, Morgan Stanley, Caterpillar, Piper Sandler, Tesla, Piper, wouldn't, it's, Baird, KeyCorp, Jefferies, it's bullish, Stock, GOOS, AppLovin, Oppenheimer Organizations: Nvidia, NVIDIA, Away Tech, Mizuho, AMD, Broadcom, UBS, Partners, Surgery Partners, Apple, VF Corp, Vans, UW, Walmart Locations: Wells Fargo, China

☆ New lawsuits against TikTok mirror those against Big Tobacco and Purdue Pharma
▼ + stars: | 2024-10-14 | by ( Kenneth Niemeyer | ) www.businessinsider.com time to read: +5 min

Attorneys general in 14 different states filed lawsuits against TikTok last week. The suits mirror earlier ones against Big Tobacco and Purdue Pharma, legal experts told BI. The Sackler family, owners of Purdue Pharma, ultimately paid over $3 billion in settlements for misleading advertising related to their products. Purdue Pharma later filed for bankruptcy, but the Supreme Court struck down a $7 billion bankruptcy plan in June that would have given the Sackler's immunity from future civil suits. With the prospect of that federal ban looming next year, a slew of federal lawsuits helps shape public opinion and "pressure lawmakers to act," Rahmani said.

Persons: —, Adam Wandt, John Jay, Wandt, It's, wouldn't, Rahmani, Sackler, TikTok Organizations: TikTok, Big Tobacco, Purdue Pharma, Service, John, John Jay School of Criminal, Big Tech, Meta, Google, NPR Locations: California, United States

☆ Zealand Pharma targeting 'next generation' of obesity drugs, CEO says
▼ + stars: | 2024-10-11 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailZealand Pharma targeting 'next generation' of obesity drugs, CEO saysZealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover speculation.

Persons: Adam Steensberg Organizations: Zealand Pharma

☆ Zealand Pharma seeks partner for its 'next generation' weight loss drug
▼ + stars: | 2024-10-11 | by ( Karen Gilchrist | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailZealand Pharma seeks partner for its 'next generation' weight loss drugCNBC's Karen Gilchrist weighs in on Zealand Pharma's "next generation" obesity drug candidate and its search for a global partner.

Persons: Karen Gilchrist Organizations: Zealand Pharma

☆ Here are Friday's biggest analyst calls: Nvidia, Tesla, Ferrari, Meta, Amazon, Eli Lilly, Walmart, Uber & more
▼ + stars: | 2024-10-11 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Goldman Sachs reiterates Nvidia as buy Goldman raised its price target to $150 per share from $135 following a series of Nvidia management meetings. Morgan Stanley names Atlassian a top pick Morgan Stanley named Atlassian a top idea and says the software company is well positioned for share gains. Morgan Stanley reiterates Eli Lilly as overweight Morgan Stanley raised its price target on the stock to $1,158 per share from $1,106. JPMorgan reiterates Amazon, Uber and Meta as top picks JPMorgan said in a note on Friday that Amazon, Uber and Meta were the firm's top three picks heading into earnings. JPMorgan upgrades Ferrari to overweight from neutral The firm says it's more constructive on the luxury automaker following a series of management meetings.

Persons: Wells, Redburn, Mercado, Morgan Stanley downgrades Qorvo, Morgan Stanley, Goldman Sachs, Goldman, Jensen Huang, Colette Kress, Stewart Stecker, Atlassian, Eli Lilly, LLY, Mizuho downgrades Mobileye, Kinder Morgan, it's bullish, Benedetto Vigna, Investor Relations Aldo Benetti, Tesla, Guggenheim Organizations: Bank of America, Broadcom, TAM, UBS, Devices, Mercado Libre, Nvidia, Pharma, Mizuho, JPMorgan, Meta, of America, Ferrari, Investor Relations, Netflix, Guggenheim, Walmart Locations: America, OW, China

☆ Novo and Eli contender Zealand Pharma heralds its obesity drug alternative: It's our 'crown jewel'
▼ + stars: | 2024-10-11 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +4 min

Jaap Arriens | NurPhotoDanish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly . Last month, Zealand Pharma announced positive top-line results from a phase 1b trial of its weight-loss drug, a GLP-1/GLP-2 receptor dual agonist called Dapiglutide. Stock Chart Icon Stock chart icon Zealand Pharma. Novo Nordisk is also experimenting with its own version of the treatment, combining the GLP-1 component Semaglutide with amylin analog Cagrilintide in a candidate called CagriSema. Syringes from weight loss drugs "Wegovy," "Ozempic" and "Mounjaro."

Persons: Jaap Arriens, Eli Lilly, Adam Steensberg, Steensberg Organizations: Zealand Pharma, Novo Nordisk, CNBC, pharma, Nordisk, Union, Getty Locations: U.S

☆ CVS, UnitedHealth say FTC should take Lina Khan and two commissioners off drug middlemen case
▼ + stars: | 2024-10-09 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

CVS Health and UnitedHealth Group are demanding Federal Trade Commission Chairwoman Lina Khan and two other commissioners recuse themselves from a lawsuit accusing the companies and other drug middlemen of boosting their profits while inflating insulin costs for Americans. In separate motions filed Tuesday night with the FTC, CVS and UnitedHealth argued that all three commissioners have an extensive track record of making public statements that indicate "serious bias" against the companies' so-called pharmacy benefit managers. CVS said those statements demonstrate that the commissioners have "prejudged this matter," so their participation in the case "violates due process." The FTC filed the suit last month against the three largest PBMs, CVS Health's Caremark, UnitedHealth Group 's Optum Rx and Cigna 's Express Scripts. The FTC has been investigating PBMs and their role in insulin prices since 2022.

Persons: Lina Khan, UnitedHealth, Khan, Alvaro Bedoya, Rebecca Kelly Slaughter, PBMs Organizations: Financial Services, General Government, Federal Trade Commission, CVS Health, UnitedHealth, Federal Trade, CVS, Amazon, FTC, Zinc Health Services, GPO, Emisar Pharma, OptumRx Locations: Rayburn, U.S, Caremark

☆ Supreme Court rejects Martin Shkreli fine appeal
▼ + stars: | 2024-10-07 | by ( Dan Mangan | ) www.cnbc.com time to read: +3 min

The Supreme Court in rejecting that request did not explain its reason for doing so. Shkreli's request that the Supreme Court take his appeal of federal court decision was his last chance to overturn the penalty related to the drug Daraprim . People pass outside the U.S. Supreme Court on October 7, 2024 in Washington, DC. Shkreli in June asked the Supreme Court to hear his appeal of that ruling, but only as it applied to the financial penalty. The attorney said that the Supreme Court should hear Shkreli's appeal to resolve the so-called circuit split on the question of a defendant's financial liability.

Persons: Martin Shkreli, Benjamin Brafman, Shkreli, pharma bro, Shkreli's Organizations: U.S, CNBC, Federal Trade Commission, pharma, Supreme, Vyera Pharmaceuticals, FTC, Circuit, Appeals Locations: Brooklyn, New York City, U.S, Washington ,, Manhattan, Shkreli, disgorgement

☆ R. Kelly: Supreme Court rejects appeal of federal sex crimes conviction
▼ + stars: | 2024-10-07 | by ( John Fritze | ) edition.cnn.com time to read: +2 min

CNN —The Supreme Court declined on Monday to hear an appeal from R. Kelly, who is currently serving a prison sentence for federal sex crime convictions. Kelly told the Supreme Court that he was wrongly retroactively prosecuted under a federal law that passed in 2003 and made the statute of limitations indefinite for sex crimes with minors. ‘Pharma Bro’ appeal also rejectedIn another case involving a prominent criminal defendant, the Supreme Court declined an appeal Monday from “Pharma Bro” Martin Shkreli, who was fighting a $64 million court-imposed penalty for inflating the price of life-saving medications. Shkreli asked the Supreme Court to review an appeals court decision from earlier this year that upheld the penalty. The Supreme Court denied both appeals on Monday without explaining its reasoning and there were no noted dissents.

Persons: Kelly, Robert Sylvester Kelly, Pharma Bro ’, “ Pharma Bro ” Martin Shkreli, Bro ”, Shkreli, “, CNN’s Elizabeth Wagmeister Organizations: CNN, Pharma, “ Pharma, Turing Pharmaceuticals, “, Supreme Locations: New York, Chicago, America

☆ Earnings season kicks off after a blowout jobs report upended investors' hopes of another interest-rate cut
▼ + stars: | 2024-10-07 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +7 min

Tech: Amazon's Prime Day kicks off tomorrow, and there are some deals on surprising items . Amazon's Prime Day kicks off tomorrow, and there are some deals on . Getty Images; Jenny Chang-RodriguezWe've already got one indication companies are in good shape: Friday's blockbuster jobs report . But another blowout report — 250,000 jobs added and at least 4% wage growth — could lead the Fed to reconsider its easing policy. In addition to the usual Prime Day gadgets, like TVs and Airpods, Amazon is dishing out deals on tents, pocket knives, and chainsaws.

Persons: —, Jenny Chang, Rodriguez, Matthew Fox, we'll, Rodriguez We've, there's, Philipp Carlsson, Chelsea Jia Feng, haven't, Donald Trump's, Tyler Le, John Tomac, that's, boomers, They're, Gen Xers, Gen Zers, Kamala Harris, Dan DeFrancesco, Jordan Parker Erb, Hallam Bullock, Grace Lett, Amanda Yen, Milan Sehmbi Organizations: Business, Service, . Tech, Amazon's, Pfizer, Wall Street, JPMorgan, Wells Fargo, Big Tech, Getty, Fed, Boston Consulting, Trump Media, Microsoft, BI, pharma, CBS, ASEAN Locations: Israel, fintech, Vientiane, Laos, New York, London, Chicago

☆ Activist investor Starboard has just informed Pfizer it has taken a significant stake
▼ + stars: | 2024-10-07 | by ( Alex Morrell | ) www.businessinsider.com time to read: +1 min

Starboard Value has taken a significant stake in Pfizer, said people familiar with the matter. Starboard has recently taken positions in Starbucks and Match. The activist investor has informed Pfizer that it has taken a significant stake in the drugmaker, people familiar with the matter told Business Insider. The Wall Street Journal earlier reported the Starboard stake. It also has a stake in Rupert Murdoch's News Corp and has pushed for a breakup of the media conglomerate.

Persons: — Organizations: Pfizer, Service, pharma, Street, Rupert Murdoch's News Corp

☆ Cheap stocks to buy in the fourth quarter, according to HSBC
▼ + stars: | 2024-10-05 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

It's officially a new trading month, and HSBC recommends investors broaden their exposure in the fourth quarter by seeking out stocks with more reasonable valuations. "These 'big' companies represent the lion's share of equity index returns year to date." HSBC has a buy rating on the stock. In all, 16 of the 29 analysts covering GM have a strong buy or buy rating, and its average price target of $54.35 implies nearly 19% upside from Friday's close, per LSEG. The remaining 11 have a buy or strong buy rating.

Persons: It's, Nicole Inui, General Motors, Goldman Sachs, Goldman Organizations: HSBC, Dow, Industrial, Nasdaq, Federal Reserve, General, GM, Pharmaceutical, Pfizer, Delta Air Lines Locations: Americas, U.S

☆ These are the most important stocks in the U.S., according to Bank of America
▼ + stars: | 2024-10-04 | by ( Pia Singh | In | ) www.cnbc.com time to read: +3 min

There are several key stocks in the U.S. investors need to be mindful of when navigating the current market environment, according to Bank of America. To capture the momentum from this rally, Bank of America screened for the most important stocks in each region of the world — including the U.S. — that have the potential to have the largest impact on portfolio performance, positive or negative. Bank of America found these stocks to be among the most important in the U.S.: Chipmaker Nvidia and oil and gas giant Exxon Mobil ranked fairly high on the firm's steady compounders list within the screen. Meta's shares are up nearly 64% year to date. Other stocks considered the most important names in the U.S. include rideshare company Uber and pharma name Eli Lilly .

Persons: Nigel Tupper, Vivek Arya's, Metaverse, Justin Post, Eli Lilly Organizations: Bank of America, Investment, U.S, Nvidia, Exxon Mobil, Exxon, Meta, Bank of America's, Uber Locations: U.S, Lebanon, Thursday's

☆ Beyond Novo: Fund manager likes this under-the-radar pharma stock with a weight loss drug in the works
▼ + stars: | 2024-10-04 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +3 min

"Maybe that weight loss product (by United Laboratories) works, maybe it doesn't. United Laboratories' price-to-earnings of 5.8 times is a fraction of the 34.3 times that Novo Nordisk is trading at, Peche added. [United Laboratories] is making smooth progress in R & D and targets to launch Liraglutide in 2024. Their comments follow United Laboratories' "faster than expected earnings" growth in the first half of the year. Analysts' average price target on United Laboratories is 12.95 Hong Kong dollars, giving it 28.2% potential upside.

Persons: Sean Peche, it's, Peche, there's, that's, Eli Lilly, Amgen, Carol Dou, Sunny Chen, UOB Kay Hian, bode Organizations: Novo Nordisk, Ranmore Fund Management, United Laboratories, Pfizer, AstraZeneca, Global Equity Fund, Hong, Hong Kong bourse, HK Locations: Hong Kong, Novo, Europe, U.S

☆ This pharma stock is set to surge 71% thanks to autoimmune disease treatment
▼ + stars: | 2024-10-03 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

Oppenheimer thinks a key treatment for a range of autoimmune diseases can be a growth catalyst for Dianthus Therapeutics stock. The firm initiated coverage of the clinical stage biotechnology company with an outperform rating and a $48 per share price target in a Wednesday note. DNTH YTD mountain Dianthus Therapeutics stock. He estimates a more than $20 billion market for this treatment. Investors will be able to gain insight into the treatment's effectiveness in clinical data that will begin to be released in mid-2025, Allred said.

Persons: Oppenheimer, Trevor Allred, Allred, DNTH103 Organizations: Dianthus Therapeutics, Therapeutics, pharma

Search resuls for: "Adienne Pharma

25 mentions found